文献速递生殖医学

赖氨酰氧化酶阻断改善多囊卵巢综合征的无排卵

Lysyl oxidase blockade ameliorates anovulation in polycystic ovary syndrome.
PubMed 文献 · Hum Reprod · 2018-01-01

研究比较多囊卵巢综合征(PCOS)患者与非PCOS患者颗粒细胞和卵泡液中赖氨酰氧化酶(LOX)与白细胞介素-1β(IL-1β)丰度,并在体外和脱氢表雄酮诱导的PCOS大鼠模型中探讨机制与干预。结果发现PCOS患者LOX与IL-1β丰度升高(P < 0.05),IL-1β经ERK1/2、JNK及c-Jun上调LOX;β-氨基丙腈(BAPN)抑制LOX可改善PCOS大鼠不规则动情周期、多囊卵巢形态和无排卵(P < 0.05),但对卵母细胞质量改善似乎无效。

要点

  • PCOS患者颗粒细胞和卵泡液中LOX与IL-1β丰度升高(P < 0.05)。
  • IL-1β通过ERK1/2、JNK及c-Jun上调LOX表达。
  • BAPN抑制LOX改善PCOS大鼠不规则动情周期、多囊卵巢形态和无排卵(P < 0.05)。

核心结论

  • PCOS卵巢存在LOX过表达,至少部分由IL-1β所致,抑制LOX活性可改善多囊卵巢形态和无排卵。

研究设计与样本

  • 比较非PCOS(n = 30)与PCOS(n = 39)患者颗粒细胞和卵泡液中LOX与IL-1β丰度。
  • 在培养的原代人颗粒细胞中检测IL-1β对LOX表达的影响及机制。
  • 在脱氢表雄酮(DHEA)诱导的PCOS大鼠模型中研究BAPN抑制LOX对PCOS状态的改善。

主要发现

  • PCOS患者颗粒细胞和卵泡液中LOX(P < 0.05)与IL-1β(P < 0.05)丰度升高。
  • IL-1β通过激活ERK1/2和JNK及随后激活转录因子c-Jun增加LOX表达。
  • BAPN抑制LOX改善PCOS大鼠不规则动情周期(P < 0.05)、多囊卵巢形态和无排卵(P < 0.05),但对卵母细胞质量改善似乎无效。

临床怎么用

  • 卵巢组织定向特异性抑制LOX联合改善卵母细胞质量的药物可能对PCOS治疗更有效。
  • 抑制LOX联合抗炎治疗可能改善PCOS的核心特征。

局限性

  • 卵巢组织定向特异性抑制LOX联合改善卵母细胞质量的药物可能对PCOS治疗更有效。
  • BAPN抑制LOX对卵母细胞质量改善似乎无效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is overexpression of lysyl oxidase (LOX), an enzyme responsible for the cross-linking of collagens, a cause of anovulation in polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: LOX overexpression was present in PCOS ovaries, due at least in part to interleukin-1β (IL-1β), and inhibition of LOX activity with β-aminopropionitrile (BAPN) ameliorated polycystic ovary morphology and anovulation. WHAT IS KNOWN ALREADY: Aberrant ovarian extracellular matrix (ECM) remodeling and inflammation may contribute to the development of PCOS. It remains unknown whether proinflammatory IL-1β is a contributing factor for LOX overexpression in PCOS ovaries and whether inhibition of LOX can improve PCOS conditions. STUDY DESIGN, SIZE, DURATION: LOX and IL-1β abundance in the granulosa cells and follicular fluid was compared between non-PCOS (n = 30) and PCOS (n = 39) patients. The effect and mechanism of IL-1β on LOX expression was examined in cultured primary human granulosa cells. The improvements in PCOS conditions by LOX inhibition with BAPN was investigated in a dehydroepiandrosterone (DHEA)-induced PCOS rat model. PARTICIPANTS/MATERIALS, SETTING, METHODS: The abundance of LOX and IL-1β was measured with quantitative real-time polymerase chain reaction (qRT-PCR), LOX activity assays and enzyme-linked immunosorbent assays (ELISA), respectively. The effect of IL-1β on LOX expression was examined in the presence or absence of inhibitors for signaling molecules and small interfering RNA-mediated knockdown of the putative transcription factor. Chromatin immunoprecipitation assays were conducted to further identify the responsible transcription factor. The role of LOX in ovulation was investigated in a DHEA-induced PCOS rat model with administration of the LOX inhibitor BAPN. The numbers of retrieved total oocytes and MII oocytes were recorded upon ovarian stimulation. MAIN RESULTS AND THE ROLE OF CHANCE: Increased abundance of LOX (P < 0.05) and IL-1β (P < 0.05) was observed in the granulosa cells and follicular fluid in PCOS patients. IL-1β increased LOX expression via activation of ERK1/2 and JNK and subsequent activation of the transcription factor c-Jun. Inhibition of LOX with BAPN ameliorated irregular estrous cyclicity (P < 0.05), polycystic ovary morphology and anovulation (P < 0.05) in PCOS rats, but appeared to be ineffective in the improvement of oocyte quality. LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: Ovarian tissue-directed specific inhibition of LOX in combination with oocyte quality-improving drugs may be more effective in the treatment of PCOS. WIDER IMPLICATIONS OF THE FINDINGS: Inflammation of the ovary is a contributing factor for the aberrant expression of LOX in the PCOS ovary, and inhibition of LOX together with anti-inflammatory therapy may improve the core features of PCOS. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by National Key R & D Program of China (2017YFC1001403) and Doctorial Innovation Fund of Shanghai Jiao Tong University School of Medicine (BXJ201718). The authors declare no competing financial interests.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Zhang C, Ma J, Wang W, et al. Lysyl oxidase blockade ameliorates anovulation in polycystic ovary syndrome. Hum Reprod. 2018. PMID: 30272163. doi:10.1093/humrep/dey292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。